semaglutide select Allocation of According to Coronary Artery Calcium and BMI: Applying the Trial to MESA Semaglutide and Cardiovascular Outcomes in

But not all of them

Data extraction and risk of bias assessment Two researchers extracted data including the characteristics of the study population (number of patients per group, age, sex, diabetic status, liver disease status [NAFLD or NASH], and BMI per group), intervention(s) (TZD or GLP-1RA, treatment duration), control(s), outcome(s), and study results for each outcome according to a predefined Excel format

Grade Study Research Group, Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N, The GSRG

Zepbound is FDA-approved for once-weekly administration

Nutrients in Energy and One-Carbon Metabolism: learning from Metformin Users